Lawrence J. Steenvoorden Net Worth

The estimated Net Worth of Lawrence J. Steenvoorden is at least $24.6 mil dollars as of 5 January 2023. Lawrence Steenvoorden owns over 53,571 units of Chembio Diagnostics stock worth over $24,643 and over the last 3 years Lawrence sold CEMI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lawrence Steenvoorden CEMI stock SEC Form 4 insiders trading

Lawrence has made over 1 trades of the Chembio Diagnostics stock since 2023, according to the Form 4 filled with the SEC. Most recently Lawrence exercised 53,571 units of CEMI stock worth $24,643 on 5 January 2023.

The largest trade Lawrence's ever made was exercising 53,571 units of Chembio Diagnostics stock on 5 January 2023 worth over $24,643. On average, Lawrence trades about 26,786 units every 0 days since 2022. As of 5 January 2023 Lawrence still owns at least 53,571 units of Chembio Diagnostics stock.

You can see the complete history of Lawrence Steenvoorden stock trades at the bottom of the page.

What's Lawrence Steenvoorden's mailing address?

Lawrence's mailing address filed with the SEC is C/O CHEMBIO DIAGNOSTICS, INC., 3661 HORSEBLOCK ROAD, MEDFORD, NY, 11763.

Insiders trading at Chembio Diagnostics

Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert y Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.

What does Chembio Diagnostics do?

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Complete history of Lawrence Steenvoorden stock trades at Chembio Diagnostics

Chembio Diagnostics executives and stock owners

Chembio Diagnostics executives and other stock owners filed with the SEC include:

• Javan Esfandiari,
  Exec. VP and Chief Science & Technology Officer
• Richard L. Eberly,
  Pres, CEO & Director
• Javan Esfandiari,
  Executive Vice President, Chief Scientific And Technology Officer
• Neil Goldman,
  Chief Financial Officer, Executive Vice President
• Katherine Davis,
  Independent Director
• John Potthoff,
  Independent Director
• Gail Page,
  Executive Chairman of the Board
• Mary Polan,
  Independent Director
• Lynn Lewis,
  Investor Relations Contact Officer
• Chuck Caso,
  Vice President of Sales and Marketing for North America
• Richard Eberly,
  President, Chief Executive Officer, Director
• Stella Rivera,
  VP of HR
• Atif Rizvi,
  VP of Fin.
• Dr. Konstantin Lyashchenko,
  Research Director of Chembio Diagnostic Systems Inc
• Charles Caso,
  VP of Sales & Marketing
• Paul J. Angelico,
  VP of Global Operations
• Peter Kissinger,
  Director
• Richard J Larkin,
  Chief Financial Officer
• Barbara A De Buono,
  Director
• John J Iii Sperzel,
  CEO
• Robert L Aromando,
  Sr VP, Commercial Operations
• Alan Carus,
  Director
• Lawrence A. Siebert,
  President
• Leslie Teso Lichtman,
  
• Norman H Pessin Brian L. Pe...,
  
• Gary Meller,
  Director
• Sharon W Klugewicz,
  Chief Operating Officer
• David Gyorke,
  See Remarks
• Robert Passas,
  See Remarks
• Avi Pelossof,
  Vice President
• Gerald A Eppner,
  Director
• James D Merselis,
  Director
• Capital Master Llc Crestvie...,
  
• David Acheson,
  
• Credit Advisors, Llcpercept...,
  
• David William Bespalko,
  
• Lawrence J. Steenvoorden,
  See remarks
• Charles Caso,
  See Remarks
• Paul Angelico,
  See remarks